“We want to better understand the role of each micro-organism in skin beauty and build new skin models to study effects of active ingredients,” said David Herault, head of global research and development for Bio-Actives at BASF.
One of the first achievements of the research team, in collaboration with the International Center for Infectiology Research (CIRI), has been creating newly engineered skin models embedded with bacteria, which allow researchers to explore the interactions between active ingredients and skin microflora.
To reverse dehydration and correct skin dryness, BASF has developed Relipidium. Based on in vivo results on microbiota, it is the first active ingredient that rebalances the skin’s ecosystem to restore the skin barrier and correct skin dryness: it stimulates the synthesis of lipids in the epidermis, thus speeding up barrier recovery and strengthening the skin’s defense. Relipidium rebalances the skin without negatively affecting skin microflora. It is obtained through bacterial fermentation – yeast hydrolysate, biofermented by lactobacillus plantarum – and contains no antibiotic or prebiotic activities.
Relipidium has been demonstrated in vivo to significantly increase skin hydration by 12% and to allow an increase of the beneficial germ staphylococcus epidermidis by factor two, both within two weeks. Dry skin dysbiosis was rebalanced, the ratio of staphylococcus epidermidis versus the pathogenic germ staphylococcus aureus was increased by factor 2.3. Relipidium is incorporated into the final process below 30°C, or at room temperature for cold processing. The recommended dose is 1-2%.